Literature DB >> 29749635

Microbial and metabolic multi-omic correlations in systemic sclerosis patients.

Chiara Bellocchi1, Álvaro Fernández-Ochoa2, Gaia Montanelli1, Barbara Vigone1, Alessandro Santaniello1, Christian Milani3, Rosa Quirantes-Piné2, Isabel Borrás-Linares2, Marco Ventura3, Antonio Segura-Carrettero2, Marta Eugenia Alarcón-Riquelme4,5, Lorenzo Beretta1.   

Abstract

Intestinal microbiota has been associated with systemic autoimmune diseases, yet the functional consequences of these associations are elusive. We characterized the fecal microbiota (16S rRNA gene amplification and sequencing) and the plasma metabolome (high-performance liquid chromatography coupled to mass spectrometry) in 59 patients with systemic sclerosis (SSc) and 28 healthy controls (HCs). Microbial and metabolic data were cross-correlated to find meaningful associations after extensive data mining analysis and internal validation. Our data show that a reduced model of nine bacteria is capable of differentiating HCs from SSc patients. SSc gut microbiota is characterized by a reduction in protective butyrate-producing bacteria and by an increase in proinflammatory noxious genera, especially Desulfovibrio. From the metabolic point of view, a multivariate model with 17 metabolite intermediates well distinguished cases from controls. The most interesting peaks we found were identified as glycerophospholipid metabolites and benzene derivatives. The microbial and metabolic data showed significant interactions between Desulfovibrio and alpha-N-phenylacetyl-l-glutamine and 2,4-dinitrobenzenesulfonic acid. Our data suggest that in SSc, intestinal microbiota is characterized by proinflammatory alterations subtly entwined with the metabolic state. Desulfovibrio is a relevant actor in gut dysbiosis that may promote intestinal damage and influence amino acid metabolism.
© 2018 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.

Entities:  

Keywords:  gastrointestinal; metabolome; microbiota; systemic sclerosis

Mesh:

Year:  2018        PMID: 29749635     DOI: 10.1111/nyas.13736

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

Review 1.  Gastrointestinal tract microbiota modifications in systemic sclerosis.

Authors:  Elizabeth R Volkmann; Anna-Maria Hoffmann-Vold
Journal:  Eur J Rheumatol       Date:  2019-12-19

Review 2.  Update on the Gastrointestinal Microbiome in Systemic Sclerosis.

Authors:  Chiara Bellocchi; Elizabeth R Volkmann
Journal:  Curr Rheumatol Rep       Date:  2018-06-25       Impact factor: 4.592

3.  Metabolic Profiling of Blood and Urine for Exploring the Functional Role of the Microbiota in Human Health.

Authors:  Ana F Diallo; Mark B Lockwood; Katherine A Maki; Alexis T Franks; Abhrarup Roy; Rosario Jaime-Lara; Paule V Joseph; Wendy A Henderson; Seon Yoon Chung; Jacqueline McGrath; Stefan J Green; Anne M Fink
Journal:  Biol Res Nurs       Date:  2020-07-29       Impact factor: 2.522

4.  Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.

Authors:  Anna-Maria Hoffmann-Vold; Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-20

5.  Serum metabolite differences detected by HILIC UHPLC-Q-TOF MS in systemic sclerosis.

Authors:  Chen Sun; Huimin Zhu; Yun Wang; Yichen Han; Dongdong Zhang; Xi Cao; Mihribangvl Alip; Min Nie; Xue Xu; Liangjing Lv; Xuebing Feng; Lingyun Sun; Dandan Wang
Journal:  Clin Rheumatol       Date:  2022-09-20       Impact factor: 3.650

Review 6.  Microbiome Changes in Connective Tissue Diseases and Vasculitis: Focus on Metabolism and Inflammation.

Authors:  Lidia La Barbera; Federica Macaluso; Serena Fasano; Giulia Grasso; Francesco Ciccia; Giuliana Guggino
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

Review 7.  Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases.

Authors:  Yanfeng Bao; Chen Dong; Juan Ji; Zhifeng Gu
Journal:  Clin Rheumatol       Date:  2020-06-09       Impact factor: 2.980

Review 8.  A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.

Authors:  Shannon Teaw; Monique Hinchcliff; Michelle Cheng
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580

9.  Gut Microbiota Aberration in Patients of Systemic Sclerosis and Bleomycin-Induced Mice Model.

Authors:  Jungen Tang; Xin Zhou; Xuefen Wu; Shengyan Lin; Bingxia Ming; Jixin Zhong; Baoju Wang; Lingli Dong
Journal:  Front Cell Infect Microbiol       Date:  2021-05-28       Impact factor: 5.293

10.  The efficacy and safety of fecal microbiota transplantation in the treatment of systemic sclerosis: A protocol for systematic review and meta analysis.

Authors:  Shixiong Zhang; Jingjing Lv; Xuetong Ren; Xinyu Hao; Pingping Zhou; Yangang Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.